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Abstract: Tight glycaemic control (TGC) has emerged as a major focus in critical care. However, 
repeating the initial successful reductions in reducing mortality and other outcomes via TGC has proven 
very difficult. Hence, there has been growing debate over the necessity of TGC, its goals, safety from 
hypoglycemia, and target cohorts. This article reviews existing knowledge and results to provide a new 
interpretation and explanation for the variable results in applying TGC. It then uses a validated metabolic 
system model to show how the root cause is the intra- and inter- patient variability, which makes TGC 
difficult over diverse cohorts and thus yields such variable results over many protocols. 
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1. INTRODUCTION 
1.1 The Physiological and Clinical Problem  
Critically ill patients often experience stress-induced 
hyperglycemia and high insulin resistance (McCowen et al., 
2001). It is strongly associated with increased mortality 
(Krinsley, 2003). Hyperglycaemia is also associated with 
increases in other negative clinical outcomes, including 
infection (Bistrian, 2001), sepsis and septic shock (Das, 2003, 
Marik and Raghavan, 2004), myocardial infarction (Capes et 
al., 2000), and polyneuropathy and multiple-organ failure 
(Van den Berghe et al., 2001). 
In specific, a strong counter-regulatory (stress) hormone 
response is further aggravated by pro-inflammatory immune 
responses (Fernandez-Real et al., 2003), which stimulate 
endogenous glucose production (EGP) and can inhibit insulin 
production and/or action to a variable extent, thus increasing 
insulin resistance. Absolute and relative insulin deficiency is 
a further cause. Finally, high glucose content nutritional 
regimes exacerbate hyperglycemia and thus mortality 
(Krishnan et al., 2003), whereas reducing glucose intake has 
reduced glycemic levels (Ahrens et al., 2005).  
The problem is summarised as a strong counter-regulatory 
hormone driven stress response that induces significant 
insulin resistance and can antagonise insulin production and 
action. Coupled with unsuppressed EGP and potentially 
excessive nutritional inputs, high blood glucose is inevitable. 
Dynamic patients whose condition, and thus insulin 
resistance, evolves regularly and sometimes acutely, provide 
a further challenge to providing consistent TGC across a 
every individual patient in a cohort. 
1.2 Hyperglycaemia, TGC and Outcome 
Van den Berghe et al (2001), obtained significant mortality 
reductions for a cardiovascular surgery cohort, as well as 
reducing other outcomes and treatments. It was matched by 
the retrospective study of Krinsley (2004). Van den Berghe et 
al (2006) was less successful with a more dynamic medical 
ICU cohort. Finally, the SPRINT study obtained significant 
mortality reductions for a medical ICU cohort controlling 
both nutrition and insulin inputs (Chase et al., 2008b). 
However, several studies got no similar result (Treggiari et 
al., 2008, De La Rosa et al., 2008, Meijering et al., 2006), 
with some stopped for safety due to hypoglycemia 
(Brunkhorst et al., 2008, Devos and Preiser, 2007).  
Hence, there is significant controversy around TGC and its 
application (Wilson et al., 2007, Mesotten, 2008, Finfer and 
Delaney, 2008, Devos and Preiser, 2007). This paper posits 
that it is a lack of understanding of both the problem and the 
patient dynamics that hinder clarity on all of these issues. 
2. KNOWN FACTS AND HOW TGC REALLY WORKS 
The following are well reported in this area: 
• Mortality increases with mean, maximum or range of 
blood glucose, particularly in uncontrolled cohorts 
(Krinsley, 2003, Umpierrez et al., 2002). 
• Mortality increases with blood glucose variability, 
independent of mean or median value (Egi et al., 2006, 
Krinsley, 2008). 
• Blood glucose levels over 7.0-8.0 mmol/L reduce and/or 
eliminate the effectiveness immune response to infection 
(Weekers et al., 2003, Fernandez-Real et al., 2003). 
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This article would add the following points to consider: 
• Mortality is an individual outcome, and not a cohort 
outcome. Even if its rate is measured by cohort. 
• Patients are individual and dynamic in their condition, 
with glucose levels or/and insulin resistance being a 
marker of severity of disease (Chase et al., 2006). 
• Thus, glucose response is an individual outcome. 
Specifically, the benefits of TGC work at an individual level. 
Only those patients who are tightly controlled will receive 
benefit. Hence, TGC is effective for a cohort only if it is 
(relatively) effective for every patient. In contrast to the same 
cohort result with a wide spread in TGC efficacy. Thus, it 
implies that per-patient results, rather than cohort based 
results, should be the goal of any TGC protocol. 
Only a few trials have reported per patient results (Chase et 
al., 2008b, Goldberg et al., 2004, Van den Berghe et al., 
2003). More importantly, Table 1 summarises the cohort 
results from several trials in terms of median and (lognormal 
multiplicative) variance. It clearly shows that there is no clear 
correlation between clinical “success” and glycemia.  
Table 1: Cohort-based clinical trial results. Where Leuven 
2001/2006, Krinsley and SPRINT were “successful”. Control 
or retrospective groups are all assumed “unsuccessful”.  
* All values converted to lognormal median (geometric mean) and 
multiplicative variance (σ*) 
In particular, it should be noted that SPRINT statistically 
decoupled all glucose metrics (mean, variability, peak/range) 
from mortality across the TGC cohort (p < 0.05). Thus, there 
was no relationship between any glucose metric and 
mortality, meaning that survivors and non-survivors received 
equivalent tight control over all patients.  
More succinctly, TGC with SPRINT eliminated glycemia as 
an indicator of mortality over a 384 patient cohort. Given that 
the SPRINT TGC group had lower mortality than the 
retrospective comparison cohort, it can be directly assumed 
that no other risk factor increased (significantly enough) to 
offset this decoupling of glycemia and mortality. In specific, 
it can thus be assumed that SPRINT reduced mortality 
directly via TGC. 
Finally, the only other study that analysed glucose and 
mortality within the TGC cohort still showed a link between 
them (Van den Berghe et al., 2003). 
As a statistical note, Table 1 uses lognormal statistics because 
TGC data is often skewed. While arithmetic mean is typically 
used to report central tendency, it is not a robust statistic, as it 
is greatly influenced by outliers. For skewed distributions, the 
arithmetic mean will not match the notion of "middle", and 
robust lognormal or non-parametric statistics provide a much 
better definition of central tendency. 
There are three direct conclusions that can be drawn: 
1. Conclusion 1: It is per-patient glycemic results that are 
important, rather than over a cohort, since mortality is an 
individual response to condition and therapy.  
2. Conclusion 2: The true goal of TGC should be to 
statistically decouple glycemia (mean, variability, etc) 
from mortality across a tightly controlled cohort.  
3. Conclusion 3: Median blood glucose levels should be 
less than ~7.0 mmol/L, and thus allow for reasonable 
variation in control as patient condition evolves. 
The first point thus asks how does the median patient and 
their associated 5th, 25th, 75th and 95th percentile compatriots 
respond to TGC? This answer will determine whether all 
patients in a cohort, regardless of outcome, receive the same 
level of control, which is critical to making any comparison. 
In particular, comparing mortality between a TGC and 
control or retrospective cohort implicitly assumes that the 
control received within each cohort was equivalent for all 
patients, thus rendering the comparison of mortality valid. If 
this assumption doesn’t hold then it is not possible to 
determine the impact of TGC or glycemic control in general, 
because it is not possible to verify that survivors or non-
survivors in either cohort had a significantly different 
glycemic outcome. 
The second point implies that the real goal of TGC should be 
assessed for each patient, rather than as a cohort. Decoupling 
glycemia from mortality will not likely raise mortality given 
the evidence, and any such a rise would thus be indicative of 
other factors outside of the TGC intervention. It has the 
added advantages of eliminating the given ICUs mortality 
rate before TGC, as it considers only the TGC cohort, thus 
also simplifying trial design and cohorts required. 
The last point simply follows from studies on immune 
response efficacy in hyperglycemia. This paper recommends 
a median target of 7.0 mmol/L or less to allow for variation 
and patient evolution, while keeping blood glucose less than 
8.0 mmol/L. However, given the association between 
glycemia and severe infection, lower may be better. 
Summary: These conclusions imply that measuring glycemic 
control over entire cohorts for comparison is not valid. 
Critically, most prior studies have not done the analyses to 
determine whether their TGC protocols were effective 
Trial 
Median 
(mmol/L) 
Variance 
σ* 
Leuven 2001 5.6 1.20 
Leuven 2001 Control 8.3 1.24 
Krinsley 6.7 1.50 
Krinsley Retrospective 7.2 1.76 
Leuven 2006 - all 6.0 1.29 
Leuven 2006 Control - all 8.3 1.22 
Leuven 2006 - LoS ≥ 3 day 5.8 1.27 
Leuven 2006 Cont. - LoS≥3 day 8.6 1.17 
Treggiari et al – Control / None 7.7 1.30 
Treggiari et al – 4-7 mmo/L goal 7.5 1.28 
Treggiari et al – 4-6 mmol/L goal 7.0 1.26 
SPRINT 5.8 1.24 
SPRINT Retrospective 7.2 1.88 
VISEP IIT all  6.1 1.17 
VISEP Conventional all 8.2 1.24 
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enough across all types of patient to provide a valid 
comparison to mortality in the randomised control or 
retrospective cohorts used.  
Thus, the goal of any TGC protocol should be to (first) 
decouple glycemia from outcome in the TGC cohort, before 
comparison to a control. If mortality is thus lower under 
TGC, it can be assumed that other indices of risk were not 
(significantly) elevated enough to offset them. 
The remaining question: How to achieve such tight control 
and/or conversely, what physiological behaviours have made 
these goals difficult to achieve in practice. 
3. INSULIN SENSITIVITY & PATIENT-SPECIFIC TGC 
Glycemia in the critically ill generally reflects patient 
condition. The more critically ill, the more variable and 
greater their glycemia, as seen in several studies (Chase et al., 
2006). However, glycemia merely reflects three factors: 
• Nutritional inputs (carbohydrate content in specific) 
• Insulin (endogenous and exogenous) 
• Insulin sensitivity (SI hereafter) 
A typical TGC control protocol controls only insulin dosing, 
excepting SPRINT which controls both insulin and nutrition. 
Many studies leave nutritional inputs to unit specific 
standards and/or don’t report them. However, the glycemic 
response to be controlled is the response to both inputs.  
Thus, insulin sensitivity is the primary factor. It determines 
the resulting glucose level for any given inputs, and thus how 
much insulin is required to achieve tight control, at least to 
the dose where insulin effect saturates (Natali et al., 2000). 
More specifically, in this model it accounts for the net affect 
of any suppression or increase in endogenous insulin and 
glucose production, and the rate of peripheral glucose uptake. 
Finally, the cytokines and hormones that drive these affects 
that result in hyperglycemia are physiologically linked to 
lowered insulin sensitivity and vary continuously over time 
as patient condition evolves. Hence, this overall effective 
insulin sensitivity is dynamic and time-varying. 
3.1 Insulin Sensitivity in the Critically Ill 
A clinically validated model is used to identify patient-
specific, time-varying (hourly) insulin sensitivity every hour:  
 
Where G(t) [mmol/L] is plasma glucose I(t) [mmol/L] is 
plasma insulin, uex(t) [mU/min] is exogenous insulin input, 
basal endogenous insulin secretion is IB [mU/L/min], with kI 
representing suppression of basal insulin secretion by 
exogenous insulin. Interstitial insulin is Q(t) [mU/L], with k 
[1/min] accounting for losses and transport. Body weight and 
brain weight are denoted by mbody [kg] and mbrain [kg]. Patient 
endogenous glucose clearance and insulin sensitivity are pG 
[1/min] and SI [L/(mU.min)]. The parameter VI,frac [L/kg] is 
the insulin distribution volume per kg body weight and n 
[1/min] is the transport rate of insulin from plasma. Total 
plasma glucose input is P(t) [mmol/min], endogenous 
glucose production is PEND [mmol/kg/min] and VG,frac [L/kg] 
represents the glucose distribution volume per kg body 
weight. CNS [mmol/kg/min] captures non-insulin mediated 
glucose uptake by the central nervous system. Michaelis-
Menten functions model saturation, with αI [L/mU] for the 
saturation of plasma insulin disappearance, and αG [L/mU] 
for insulin-dependent glucose clearance saturation.  
These parameters and their clinically validated values are 
well documented in the literature (Lin et al., 2008). 
Additionally, they have been used in several clinical TGC 
studies including the development of SPRINT. 
For this study, two cohorts are analysed: 
• Adult ICU (ICU): N = 384 patients from SPRINT with 
over 40k hours of data (Chase et al., 2008b) 
• Neonatal ICU (NICU): N = 25 patients and over 3500 
hours of data (LeCompte et al., 2008) 
For each cohort, insulin sensitivity, SI, is identified hourly 
from the clinical data. In each cohort, the hour to hour 
variation in SI(t) for each patient is used to generate a 
stochastic model giving the probability distribution for hourly 
variation in SI from any current value of SI (Lin et al., 2008). 
Fig. 1 shows the SI distribution for each cohort. It is clear that 
the NICU cohort has a far wider and flatter distribution of 
values. Theses results indicate a lesser level of whole body 
insulin resistance compared to adults. They also show a 
greater inter-patient variability in this parameter. For context, 
Fig. 1 also shows the typical values found in studies on type 
2 diabetic individuals (Lotz, 2007). 
 
Fig. 1: ICU and NICU distributions of SI. 
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In detail, the ICU cohort, the median SI-ICU = 0.22x10-3 (IQR: 
[0.14-0.33]x10-3; 90%CI: [0.06-0.78]x10-3) L/(mU.min). For 
the NICU cohort, median SI-NICU = 0.67x10-3 (IQR: [0.43-
0.95]x10-3; 90%CI: [0.17-1.47]x10-3) L/(mU.min). For 
context, the range in healthy T2DM, SI-T2DM = [1, 2.5]x10-3 
L/(mU.min) (Lotz, 2007). 
Fig. 2 shows the ICU and NICU stochastic models, capturing 
hourly variation from SI,n to SI,n+1. The lines indicate the 
median, IQR and 90%CI for SI,n+1 in the next hour on a 
vertical line from the current hour value, SI,n value on the x-
axis. Most variation is in a narrow band that grows wider 
with a downward skew, as SI,n rises (becoming more ill). 
Note the NICU axes are ~2x larger. 
Fig. 2 shows generally smaller variations at similar SI,n for the 
NICU case. Fig. 3 shows this variation in percent (from 
median) for each cohort in cumulative distribution functions. 
Median values for the 1-hour changes ∆SI-ICU and ∆SI-NICU are 
zero (p < 0.01). However, their IQR ranges are different 
(IQR: ∆SI-NICU = [-7.5, +9.8]; ∆SI-ICU = [-11.3, +15.7])% 
(p=0.02) with the IQR range of ∆SI-NICU is 40% smaller than 
the IQR range for ∆SI-ICU. The same results hold true for 
variations over 2, 3 and 4 hours, with the range of IQR for 
∆SI increasing over time to up to 60% (of median). Hence, 
adult ICU patients have greater intra-patient variation in SI. 
 
Fig. 2: ICU (top) and NICU (bottom) stochastic models 
showing hour to hour variation in SI. Note axes are different. 
 
Fig. 3: 1-hourly variations (%), ∆SI, for ICU and NICU. 
Summary: Adult ICU patients have significantly more intra-
patient variation in SI compared to NICU patients, and are 
thus far more dynamic in their evolution, which might be 
expected clinically. It is also clear ICU patients have far less 
inter-patient variability than NICU patients. Thus, each 
cohort has a significant form of variability to be managed.  
3.2 Summary and Implications for TGC Protocol Design 
This analysis of SI in two distinctly different critical care 
cohorts has significant implications for TGC protocols: 
• To be patient specific a TGC protocol must directly (e.g. 
model-based) or indirectly account for both intra- and 
inter- patient variability. 
• Measurement frequency must be 1-3 hourly and is likely 
to vary with patient condition and stability. 
Currently, only a very few protocols either directly or 
indirectly adapt their intervention based on patient insulin 
sensitivity (Chase et al., 2008b, Wong et al., 2006, Plank et 
al., 2006, Braithwaite et al., 2006, Goldberg et al., 2004). 
Most are model-based. Some others, such as Clarian and 
Glucommander adjust based on insulin sensitivity, but are 
blinded to carbohydrate intake, so they only get a relative 
measure that is not full accurate. In further contrast, some 
clinical protocols account for increasing resistance (falling SI) 
by increasing insulin dose, but do not formally adjust the 
other way, despite evidence of such changes in Fig 2 and 
other clinical studies. All of these issues are aggravated by 
often extended measurement periods out to 4-hourly, where 
variability can be quite wide, as evident from Figures 2-3. 
Measurement frequency and clinical burden are major issues 
(Chase et al., 2008a). The IQR range for variations in SI at 3 
and 4 hours approaches 60% (± ~30%), leading to significant 
variations in glycemic response for a given intervention. 
Given the prevalence of continuous infusions held over such 
longer intervals, even relatively modest variation (10-20% 
over 3-4 hours) would result in significant changes in glucose 
from the intended outcome. Hence, as measurement periods 
rise so does both glycemic variability and hypoglycemia 
(Lonergan et al., 2006, Chase et al., 2006).  
Given that some patients are more variable than others, 
failure to directly identify and account for patient variability 
means that some patients will receive, all else equal, more 
variable TGC. Thus, such clinical protocols are likely to fail 
in returning a mortality result, despite showing a good overall 
glycemic response for the cohort, as is seen comparing results 
across Table 1. Hence, fixed protocols that provide dosing 
based on more fixed parameters or protocols, rather than 
patient-specific responses are likely to fail. 
For example, the NICU based NIRTURE trial (Beardsall et 
al., 2008) provided dosing on a fixed mU/g body weight. 
They adjusted them on a fixed sliding scale to account for 
increasing insulin resistance but had little mechanism for 
lowering insulin dosage before hypoglycemia. As a result, it 
could not adapt to the wide range inter-patient variability in 
insulin sensitivity in neonates seen in Fig. 1, or to the modest 
intra-patient variability seen in Fig. 2. Long measurement 
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periods out to 4-6 hours, with constant infusions in between 
exacerbated the problems with the resulting control. The end 
result was high glycemic variability with excessive 
hypoglycemia that stopped the trial early.   
Similarly, the Leuven protocol was more successful with a 
less acutely ill and thus potentially less variable 
cardiovascular surgery cohort in 2001 than for the more 
critically ill medical ICU cohort in 2006. This protocol also 
had similar elements of long measurement periods based on 
patient glucose levels, rather than any indication of stability. 
In contrast, SPRINT increases measurement intervals only 
after several measurements in a tight band at pre-set levels of 
interventions that indicate high insulin sensitivity. The 
difference is in adjusting based on patient stability in both 
glycemic response and insulin sensitivity, rather than on a 
particular glucose level. 
Lonergan et al (2006) demonstrated these results in a protocol 
comparison using a validated virtual trial approach. The 
results indicated that any system that did not adapt 
intervention and/or measurement period based on patient-
specific metrics, as do model-based and similar systems (e.g. 
SPRINT), would be unable to provide the same level of 
glycemic control for all patients. Thus, the primary 
implication is simply that for TGC to provide equal control to 
all patients, the control protocol must also be patient-specific. 
Finally, most protocols that have not yielded full success are 
typically blinded to the nutritional intake. Thus, they cannot 
be patient-specific. In particular, it is the interaction between 
insulin sensitivity (resistance-1), insulin and nutrition that 
determines glycemic outcome. Not knowing one of these 
variables means patient-specific control cannot be delivered. 
Summary: A TGC cohort result may have acceptable median 
and variability, as seen in Table 1, but the clinical outcome 
will be highly dependent on how each patient is treated. 
Failure to account for inter- and intra- patient variability will 
result in poor TGC for the more dynamic patients (intra-
patient variability) or those for whom dosing is inappropriate 
due to inter-patient variability. Managing variability means 
that any protocol must be able to adapt and provide patient 
specific interventions that evolve with patient condition. 
Finally, measurement frequencies must be short enough to 
minimise potential variation between interventions. At 1-3 
hours for maximum sampling periods, protocols must also be 
designed to minimise clinical burden. Failing these issues, 
glycemic markers may not be eliminated as a marker for 
mortality, thus rendering any further clinical comparisons 
difficult or not valid.  
4. CONCLUSIONS 
The field of critical care has seen a great deal of debate over 
TGC therapy and its efficacy. This article has attempted to 
show that much of the difficulty may be due to incorrect 
targets in creating TGC protocols or applying TGC therapy, 
by using a cohort based measure of glycemic control to see 
changes in mortality, which is an individual outcome. 
Secondly, it shows that the difficulty in translating cohort-
based control to individual outcomes is likely the result of 
patient variability, as seen by variations in insulin sensitivity. 
Finally, both parts of the paper outlined distinct metrics 
and/or goals, based on this analysis and prior successful 
results, to provide potential directions and goals for designing 
and implementing the next generation of TGC protocols. 
4. REFERENCES 
Ahrens, C. L., Barletta, J. F., Kanji, S., Tyburski, J. G., 
Wilson, R. F., Janisse, J. J. & Devlin, J. W. (2005) 
Effect of low-calorie parenteral nutrition on the 
incidence and severity of hyperglycemia in surgical 
patients: a randomized, controlled trial. Crit Care Med, 
33, 2507-12. 
Beardsall, K., Vanhaesebrouck, S., Ogilvy-Stuart, A. L., 
Vanhole, C., Palmer, C. R., Van Weissenbruch, M., 
Midgley, P., Thompson, M., Thio, M., Cornette, L., 
Ossuetta, I., Iglesias, I., Theyskens, C., De Jong, M., 
Ahluwalia, J. S., De Zegher, F. & Dunger, D. B. (2008) 
Early insulin therapy in very-low-birth-weight infants. 
N Engl J Med, 359, 1873-84. 
Bistrian, B. R. (2001) Hyperglycemia and Infection: Which is 
the Chicken and Which is the Egg? JPEN J Parenter 
Enteral Nutr, 25, 180-181. 
Braithwaite, S. S., Edkins, R., Macgregor, K. L., Sredzienski, 
E. S., Houston, M., Zarzaur, B., Rich, P. B., Benedetto, 
B. & Rutherford, E. J. (2006) Performance of a dose-
defining insulin infusion protocol among trauma service 
intensive care unit admissions. Diabetes Technol Ther, 
8, 476-88. 
Brunkhorst, F. M., Engel, C., Bloos, F., Meier-Hellmann, A., 
Ragaller, M., Weiler, N., Moerer, O., Gruendling, M., 
Oppert, M., Grond, S., Olthoff, D., Jaschinski, U., John, 
S., Rossaint, R., Welte, T., Schaefer, M., Kern, P., 
Kuhnt, E., Kiehntopf, M., Hartog, C., Natanson, C., 
Loeffler, M. & Reinhart, K. (2008) Intensive insulin 
therapy and pentastarch resuscitation in severe sepsis. N 
Engl J Med, 358, 125-39. 
Capes, S. E., Hunt, D., Malmberg, K. & Gerstein, H. C. 
(2000) Stress hyperglycaemia and increased risk of 
death after myocardial infarction in patients with and 
without diabetes: a systematic overview. Lancet, 355, 
773-778. 
Chase, J., Andreassen, S., Jensen, K. & Shaw, G. (2008a) 
The Impact of Human Factors on Clinical Protocol 
Performance - A proposed assessment framework and 
case examples. Journal of Diabetes Science and 
Technology (JoDST), 2, 409-416. 
Chase, J., Shaw, G. M., Wong, X. W., Lotz, T., Lin, J. & 
Hann, C. E. (2006) Model-based Glycaemic Control in 
Critical Care - A review of the state of the possible. 
Biomedical Signal Processing and Control, 1, 3-21. 
Chase, J. G., Shaw, G., Le Compte, A., Lonergan, T., 
Willacy, M., Wong, X. W., Lin, J., Lotz, T., Lee, D. & 
Hann, C. (2008b) Implementation and evaluation of the 
SPRINT protocol for tight glycaemic control in 
critically ill patients: a clinical practice change. Crit 
Care, 12, R49. 
Das, U. N. (2003) Insulin in sepsis and septic shock. J Assoc 
Physicians India, 51, 695-700. 
De La Rosa, C., Donado, J. H., Restrepo, A. H., Quintero, A. 
M., Gonzalez, L. G., Saldarriaga, N. E., Bedoya, M., 
5
  
     
 
Toro, J. M., Velasquez, J. B., Valencia, J. C., Arango, 
C. M., Aleman, P. H., Vasquez, E. M., Chavarriaga, J. 
C., Yepes, A., Pulido, W. & Cadavid, C. A. (2008) 
Strict glycaemic control in patients hospitalised in a 
mixed medical and surgical intensive care unit: a 
randomised clinical trial. Crit Care, 12, R120. 
Devos, P. & Preiser, J. C. (2007) Current controversies 
around tight glucose control in critically ill patients. 
Curr Opin Clin Nutr Metab Care, 10, 206-9. 
Egi, M., Bellomo, R., Stachowski, E., French, C. J. & Hart, 
G. (2006) Variability of blood glucose concentration 
and short-term mortality in critically ill patients. 
Anesthesiology, 105, 244-52. 
Fernandez-Real, J. M., Broch, M., Richart, C., Vendrell, J., 
Lopez-Bermejo, A. & Ricart, W. (2003) CD14 
monocyte receptor, involved in the inflammatory 
cascade, and insulin sensitivity. The Journal of clinical 
endocrinology and metabolism, 88, 1780-1784. 
Finfer, S. & Delaney, A. (2008) Tight glycemic control in 
critically ill adults. Jama, 300, 963-5. 
Goldberg, P. A., Sakharova, O. V., Barrett, P. W., Falko, L. 
N., Roussel, M. G., Bak, L., Blake-Holmes, D., Marieb, 
N. J. & Inzucchi, S. E. (2004) Improving glycemic 
control in the cardiothoracic intensive care unit: clinical 
experience in two hospital settings. J Cardiothorac Vasc 
Anesth, 18, 690-7. 
Krinsley, J. S. (2003) Association between hyperglycemia 
and increased hospital mortality in a heterogeneous 
population of critically ill patients. Mayo Clin Proc, 78, 
1471-1478. 
Krinsley, J. S. (2008) Glycemic variability: a strong 
independent predictor of mortality in critically ill 
patients. Crit Care Med, 36, 3008-13. 
Krishnan, J. A., Parce, P. B., Martinez, A., Diette, G. B. & 
Brower, R. G. (2003) Caloric intake in medical ICU 
patients: consistency of care with guidelines and 
relationship to clinical outcomes. Chest, 124, 297-305. 
Lecompte, A., Chase, J., Shaw, G., Lynn, A. & Russell, G. 
(2008) Blood glucose modelling and control for pre-
term infants. 2008 Engineering & Physical Sciences in 
Medicine and Australian Biomedical Engineering 
Conference (EPSM ABEC 2008). Christchurch, New 
Zealand, ABEC. 
Lin, J., Lee, D., Chase, J. G., Shaw, G. M., Le Compte, A., 
Lotz, T., Wong, J., Lonergan, T. & Hann, C. E. (2008) 
Stochastic modelling of insulin sensitivity and adaptive 
glycemic control for critical care. Comput Methods 
Programs Biomed, 89, 141-52. 
Lonergan, T., Lecompte, A., Willacy, M., Chase, J. G., Shaw, 
G. M., Wong, X. W., Lotz, T., Lin, J. & Hann, C. E. 
(2006) A Simple Insulin-Nutrition Protocol for Tight 
Glycemic Control in Critical Illness: Development and 
Protocol Comparison. Diabetes Technol Ther, 8, 191-
206. 
Lotz, T. (2007) High Resolution Clinical Model-Based 
Assessment of Insulin Sensitivity. Mechanical 
Engineering. Christchurch, University of Canterbury. 
Marik, P. E. & Raghavan, M. (2004) Stress-hyperglycemia, 
insulin and immunomodulation in sepsis. Intensive Care 
Medicine, 30, 748-756. 
Mccowen, K. C., Malhotra, A. & Bistrian, B. R. (2001) 
Stress-induced hyperglycemia. Crit Care Clin, 17, 107-
124. 
Meijering, S., Corstjens, A. M., Tulleken, J. E., Meertens, J. 
H., Zijlstra, J. G. & Ligtenberg, J. J. (2006) Towards a 
feasible algorithm for tight glycaemic control in 
critically ill patients: a systematic review of the 
literature. Crit Care, 10, R19. 
Mesotten, D. (2008) Tight glycaemic control in the intensive 
care unit: pitfalls in the testing of the concept. Crit 
Care, 12, 187. 
Natali, A., Gastaldelli, A., Camastra, S., Sironi, A. M., 
Toschi, E., Masoni, A., Ferrannini, E. & Mari, A. 
(2000) Dose-response characteristics of insulin action 
on glucose metabolism: a non-steady-state approach. 
Am J Physiol Endocrinol Metab, 278, E794-801. 
Plank, J., Blaha, J., Cordingley, J., Wilinska, M. E., Chassin, 
L. J., Morgan, C., Squire, S., Haluzik, M., Kremen, J., 
Svacina, S., Toller, W., Plasnik, A., Ellmerer, M., 
Hovorka, R. & Pieber, T. R. (2006) Multicentric, 
randomized, controlled trial to evaluate blood glucose 
control by the model predictive control algorithm versus 
routine glucose management protocols in intensive care 
unit patients. Diabetes Care, 29, 271-6. 
Treggiari, M. M., Karir, V., Yanez, N. D., Weiss, N. S., 
Daniel, S. & Deem, S. A. (2008) Intensive insulin 
therapy and mortality in critically ill patients. Crit Care, 
12, R29. 
Umpierrez, G. E., Isaacs, S. D., Bazargan, N., You, X., 
Thaler, L. M. & Kitabchi, A. E. (2002) Hyperglycemia: 
an independent marker of in-hospital mortality in 
patients with undiagnosed diabetes. J Clin Endocrinol 
Metab, 87, 978-982. 
Van Den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., 
Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, 
P., Lauwers, P. & Bouillon, R. (2001) Intensive insulin 
therapy in the critically ill patients. N Engl J Med, 345, 
1359-1367. 
Van Den Berghe, G., Wouters, P. J., Bouillon, R., Weekers, 
F., Verwaest, C., Schetz, M., Vlasselaers, D., 
Ferdinande, P. & Lauwers, P. (2003) Outcome benefit 
of intensive insulin therapy in the critically ill: Insulin 
dose versus glycemic control. Crit Care Med, 31, 359-
366. 
Weekers, F., Giulietti, A. P., Michalaki, M., Coopmans, W., 
Van Herck, E., Mathieu, C. & Van Den Berghe, G. 
(2003) Metabolic, endocrine, and immune effects of 
stress hyperglycemia in a rabbit model of prolonged 
critical illness. Endocrinology, 144, 5329-38. 
Wilson, M., Weinreb, J. & Hoo, G. W. (2007) Intensive 
insulin therapy in critical care: a review of 12 protocols. 
Diabetes Care, 30, 1005-11. 
Wong, X. W., Singh-Levett, I., Hollingsworth, L. J., Shaw, 
G. M., Hann, C. E., Lotz, T., Lin, J., Wong, O. S. & 
Chase, J. G. (2006) A novel, model-based insulin and 
nutrition delivery controller for glycemic regulation in 
critically ill patients. Diabetes Technol Ther, 8, 174-90. 
 
 
6
